Drug Approval | March 01, 2022
USFDA approves CITI Biopharma’s Vonjo
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
110 BDS graduates admitted in week one of the launch
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Subscribe To Our Newsletter & Stay Updated
